Purva Joshi / March 9, 2026 / 4 minutes of readingDesigning Inspection-Ready GCP Quality for Scalable Clinical Development
Introduction: Why GCP Quality Must Be Designed, Not Retrofitted
The release of ICH E6 (R3) in January 2025 reflects a continued shift in regulatory expectations. Organizations must now demonstrate that clinical trial quality is intentionally embedded into trial design, governance, and execution in a manner proportionate to risk and appropriate for the stage of development.
As clinical programs expand in size and complexity, traditional, document-driven GCP quality models often struggle to scale. Fragmented SOPs, reactive remediation, and inconsistent oversight can increase inspection risk and divert attention from what matters most—participant safety and data integrity.
Celito Tech works with life sciences organizations—including early-stage biotech and clinical-stage companies—to design inspection-ready GCP Quality Assurance (QA) frameworks that are scalable by intent. Guided by ICH E6(R3) principles, Celito helps organizations move beyond reactive compliance toward practical, risk-based quality systems that support current studies and future growth.
The Changing Role of GCP QA Under ICH E6(R3)
ICH E6(R3) reinforces a pragmatic view of GCP quality, where QA functions focus on what is critical to trial quality, ensure alignment between documented processes and actual practice, and evolve as programs and portfolios grow.
While many organizations understand these expectations in principle, applying them consistently across SOPs, audits, service provider oversight, and inspection preparation remains a challenge. To bridge this gap, Celito applies a structured GCP QA enablement model using Celito’s GCP Accelerators. These accelerators are built around four core pillars that support inspection readiness in a proportionate, fit-for-purpose manner.
Before implementing a structured QA enablement model, organizations can take immediate actions to stabilize trial risk, clarify oversight, and address key quality gaps.
Immediate Quality Actions to Stabilize Trial Risk and Oversight
- Governance & Oversight Clarity: Confirm clear roles, responsibilities, and escalation pathways across the sponsor, CROs, and service providers, and define oversight expectations to support effective governance and timely decision-making.
- Focused Risk Assessment: Identify Critical-to-Quality factors through a targeted assessment to ensure oversight remains focused on activities and data that directly impact participant safety and data integrity.
- Fit-for-Purpose Quality Systems: Align SOPs and quality processes with how the trial is actually conducted, keeping controls lean, risk-based, and supported by effective training.
- Active Management Oversight: Establish routine management review of quality performance, emerging risks, and issue trends to support informed governance and ongoing regulatory readiness.
Celito’s GCP QA Enablement Model
GCP QA Pillar | Regulatory Expectation | How Celito Supports This (GCP Accelerators) | Outcome for Clients |
Governance & Risk-Based Quality Assessment | Oversight that is proportionate and focused on critical-to-quality factors | Reviews QA governance, quality systems, and trial processes through a risk-based lens, supported by elements of the GCP Assessment Toolkit. | Clear visibility into quality maturity and regulatory risk |
Quality Planning & SOP Enablement | SOPs and controls aligned to trial complexity and lifecycle | Prioritize SOPs and QA activities based on risk, trial stage, and timelines using structured tools from the GCP Starter & Scale-Up Package. | A streamlined, scalable quality framework |
Operational QA Oversight | Effective controls across audits, service providers, and issue management | Supports audits, service provider oversight, documentation review, and CAPA activities, as appropriate, using structured methodologies from the GCP Audits Toolkit. | Earlier identification of issues and sustainable compliance |
Continuous Inspection Readiness | Readiness maintained throughout the trial lifecycle | Conducts readiness assessments, TMF reviews, and inspection support activities supported by the GCP Inspection Readiness Toolkit. | Strengthened inspection preparedness |
From Framework to Day-to-Day Execution
This approach is particularly valuable for biotech organizations with lean teams, where quality systems must be fit for purpose early and evolve as clinical programs advance. In practice, Celito’s model supports GCP QA activities across the clinical development lifecycle in a way that reflects each organization’s size, maturity, and priorities.
Engagements often begin with a focused evaluation of governance structures and quality systems, followed by targeted quality planning and SOP prioritization. Where appropriate, Celito provides hands-on QA support across audits, documentation activities, service provider oversight, and CAPA management, while ensuring that ownership of the quality system remains with the client.
Rather than preparing for inspections at the last minute, organizations build inspection readiness as a continuous capability—one that strengthens oversight and reduces reactive remediation.
What Differentiates Celito’s GCP QA Approach
Celito’s GCP QA offering is defined by its emphasis on risk, scalability, and practical execution. The approach avoids unnecessary complexity, aligns QA activities with trial risk and organizational maturity, and supports integration across functions—an especially important balance for emerging biotech organizations. This is further strengthened through Celito’s GCP Accelerators, which include curated templates and practical tools to help teams operationalize fit-for-purpose SOP enablement, audit execution, and continuous inspection readiness.
Conclusion: Inspection Readiness as an Outcome of Good Design
ICH E6(R3) makes it clear that sustainable compliance depends on quality systems that are intentionally designed, proportionate to risk, and capable of evolving over time. By aligning GCP QA activities with these principles, Celito helps life sciences organizations—biotech and clinical-stage—move beyond reactive compliance toward inspection-ready quality systems that support scalable clinical development.